Cempra has two antibiotic candidates, solithromycin (CEM-101) and TAKSTA™ (CEM-102, sodium fusidate), in clinical trials. Both target the growing problem of antimicrobial resistance.
Solithromycin is a next-generation macrolide, the first fluorok...查看全文
$Cempra, Inc.(CEMP)$ PREM14A - Preliminary proxy statements relating to merger or acquisition Filed: 2017-09-07 AccNo: 0001193125-17-278283 Size: 10 MB 网页链接
$Cempra, Inc.(CEMP)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2017-08-10 AccNo: 0001193125-17-254570 Size: 60 KB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-08-10 AccNo: 0001193125-17-254563 Size: 2 MB 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-08-10 AccNo: 0001193125-17-254562 Size: 2 MBItem 1.01: Entry into a Material Definitive AgreementItem 3.02: Unregistered Sales of Equity SecuritiesItem 5.01: Changes in Control of RegistrantItem 8.01: Other EventsItem 9.01...
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-08-10 AccNo: 0001193125-17-253752 Size: 30 KB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-08-10 AccNo: 0001193125-17-253748 Size: 6 MB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-08-10 AccNo: 0001193125-17-253597 Size: 77 KB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-08-09 AccNo: 0001193125-17-252985 Size: 18 KB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-08-09 AccNo: 0001193125-17-252854 Size: 6 MB 网页链接
$Cempra, Inc.(CEMP)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-08-09 AccNo: 0001564590-17-016765 Size: 4 MB 网页链接